New Combined Growth Hormone/IGF-1 Therapy: May Aid Chronic Heart Failure Function

Share Article

Medical journal publishes expert scientific review by age management leader Cenegenics® Medical Institute and noted UCLA professor on compelling approach for potential long-term benefits

Cenegenics Las Vegas

Cenegenics Medical Institute: Headquarters for the Age Management Medicine Global Leader

The bottom line is there is very good extramental data showing that both growth hormone and especially IGF-1 can improve heart function.

Cenegenics® Medical Institute announced that the Journal of Cardiovascular Pharmacology and Therapeutics published its expert scientific review collaboration discussing how the combination of growth hormone/IGF-1 therapy may aid chronic heart failure function. The collaboration—entitled “The Potential Effects of IGF-1 and GH on Patients with Chronic Heart Failure”—was done with Dr. Ernst R. von Schwarz, professor of medicine at UCLA’s David Geffen School of Medicine. The article is a review of available published data on (1) the effect of growth hormone, (2) the effects from IGF-1 and (3) the hypothetical combination of both, as well as attempts to explain why some of the previous studies failed to show benefits vs. others that did.

Heart failure affects 5.7 million Americans, resulting in a staggering 250,000 deaths annually and significant problems despite major advances in medical management. The co-authors believe there is a definite need to identify alternate pathways for therapeutic intervention for improved outcomes, such as the IGF-1 pathway—which has been investigated as a marker for disease and mortality. More importantly, heart-failure study subjects had significantly lower growth hormone and IGF-1 compared to controls.

“The bottom line is there is very good extramental data showing that both growth hormone and especially IGF-1 can improve heart function. However, initial data from studies showed benefits, while the larger, controlled randomized trials did not. One hypothesis was that the patients may have an IGF-1 deficiency—the hormone that mediates the actions of growth hormone . . . an issue not addressed in prior studies. So what we did is look at the available data and found interesting information on the hypothetical use of the combined IGF-1/growth hormone therapy,” Schwarz said.

With that approach, Schwarz says, researchers wouldn’t be relying solely on the growth hormone effect, but on the effector hormone as well—a compelling concept that has yet to be studied on a larger scale in humans or used clinically.

Cenegenics conducts these collaborative studies via its nonprofit Cenegenics Education and Research Foundation (CERF), which also offers a CME-accredited physician training/certification program in age management medicine.

“CERF will continue to forge these types of research collaborations to investigate other avenues of the aging process—such as nutraceuticals to help slow the aging process and reduce some age-related occurrences, i.e. oxidative stress, telomere shortening and stem cell depletion," Dr. Robert D. Willix, Jr. said.

Willix is co-author on the study, a former cardiovascular surgeon and chief medical officer of Cenegenics Las Vegas as well as chief medical officer and CEO of Cenegenics Boca Raton.

For more information about Cenegenics’ highly regarded, CME-accredited Physician Training & Certification in Age Management Medicine, please visit their nonprofit Cenegenics Education and Research Foundation site.

For more information on Cenegenics, please visit their site, where you can register to read their online Healthy Aging Kit that includes the informative Guide to Healthy Aging, Executive Summary and media excerpts.

To schedule an interview, please contact Ann Castro, Cenegenics Director of Media Relations: 702.953.1588.

About Ernst R. von Schwarz, MD, PhD, FESC, FACC, FSCAI
Dr. Ernst R. von Schwarz is board certified in internal medicine by the American Board of Internal Medicine and in cardiology/cardiovascular diseases by the American Board of Internal Medicine. He is a noted professor of medicine at UCLA’s David Geffen School of Medicine. As a clinician and scientist, Schwarz has written more than 100 articles for peer-reviewed publications and has written 10 book chapters on cardiovascular medicine.

About Cenegenics
Cenegenics® Medical Institute, recognized leading authority in age management medicine, has two centers in Las Vegas, Nevada, as well as centers in Charleston, South Carolina; Boca Raton, Florida; Dallas, Texas; Arlington, Texas; Atlanta, Georgia; Chicago, Illinois; Beverly Hills, California; Philadelphia, Pennsylvania; Washington, DC; New York City, NY; Tulsa, OK; Jacksonville, FL; Atlantic City, NJ. Additional centers are scheduled to open in other major metropolitan areas in the near future. With an established presence in the medical community, Cenegenics uses a proactive approach based on solid science and comprehensive evaluation. Their established protocols have been recognized as the next generation of medical science, capturing global attention. Cenegenics offers CME-accredited physician training and certification opportunities in age management medicine via the nonprofit Cenegenics Education and Research Foundation (CERF). Headquartered in Las Vegas, Cenegenics serves more than 20,000 patients worldwide—2,000 are physicians and their families.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ann Castro, Director of Media Relations
Visit website